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Abstract 
Objectives: The objective of this study was to determine the rate of acquired immune deficiency syndrome (AIDS) in 
Zhejiang province and to identify specific factors associated with progression of this disease.
Methods: This study utilized a retrospective cohort to identify the specific factors involved in the progression of 
human immunodeficiency virus (HIV) to AIDS. We collected data of patients existing in care between 2008 and 2012 
from the national surveillance system databases. We performed our analyses using a multivariate Cox proportional 
hazards model.
Results: This study included 9216 HIV-positive patients (75.6 % male), which yielded 12,452 person-years (py) of 
follow-up-data. The AIDS progression rates were 33.9 % (2008), 33.6 % (2009), 38.1 % (2010), 30.6 % (2011) and 25.9 % 
(2012). We observed a significant reduction in the rate of progression Of HIV to AIDS post-2010 (Pearson χ2 = 4341.9, 
P < 0.001). The cumulative AIDS progression incidence rates were 33.4, 35.4, 36.4, 37.0 and 37.04 per 100 py in 1 each 
of the 5 years of follow-up. This study found that age was an independent risk factor for the progression of HIV to 
AIDS. Compared with patients infected with HIV by homosexual transmission, patients infected with HIV by hetero-
sexuals transmission or blood transfusion had a reduced hazard ratio (HR) for progression to AIDS (heterosexual trans-
mission: HR = 0.695, 0.524, P = 0.007; blood transfusion: HR = 0.524, P = 0.015). Diagnosed with HIV from 2011 to 
2012 and having a higher CD4+ cell count (350–500 cells/mm3; or >500 cells/mm3) at baseline were independently 
associated with lower rates of HIV progression to AIDS [HR = 0.382, 0.380, 0.187, P < 0.001]. Patients with a CD+ T-cell 
count of 200–350 cells/mm3 or greater than 350 cells/mm3 were less likely to develop AIDS following HIV diagnosis 
than were those patients without HAART treatment.
Conclusion: This study found a high progression rate from HIV to AIDS in HIV patients residing within Zhejiang prov-
ince from 2008 to 2010. This rate decreased after 2010, which coincided with the new criteria for HAART treatment, 
which likely contributed to the observed reduction in the rate of progression. Initiation of HAART with higher CD4+ 
T-cell count may reduce rate of AIDS progression. Based on our results, we conclude that efficient strategies for HIV 
screening, as well as early diagnosis and treatment are necessary to reduce the progression of HIV to AIDS.
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Background
Human immunodeficiency virus (HIV), the causative 
agent of acquired immune deficiency syndrome (AIDS), 
has posed a major global threat since its discovery in 1983 
[1]. Today, approximately 40 million people globally are 
infected with HIV. Specifically, in China, there is a stead-
ily increasing rate in the prevalence of HIV and subse-
quent progression to AIDS [2, 3]. In 2009, AIDS became 
the leading cause of death due to infectious agents in 
China [4]. Prior to 2009, the People’s Republic of China 
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(PRC) launched the Four Frees and One Care’ (FFOC) 
policy in 2003 to reduce the transmission of HIV. ‘Four 
Frees’ represent free antiretroviral treatment, prevention 
of mother-to-child transmission, voluntary counselling 
and testing, schooling for Children orphaned by AIDS’ 
[5]. ‘One care’ represents care and economic assistance 
to the households of people living with HIV/AIDS. In 
2010, the criteria for highly active antiretroviral therapy 
(HAART) was broadened from standards that included 
patients with a CD4+ T-cell count ≤200 cells/mm3 to 
those that included patients with a CD4+ T-cell count 
≤350 cells/mm3. This modification allowed a greater 
number of people living with HIV (PLHIV) receive free 
treatment at an earlier stage of the infection. Zhejiang 
province, located on the southern coast of China, is one 
of the most developed areas in China. In 2012, there were 
a total of 8144 HIV/AIDS patients in Zhejiang. Interest-
ingly, Zhejiang has a higher rate of HIV/AIDS patients 
than other Chinese provinces with similar populations 
and economic levels [6, 7]. Although 57.0 % of the total 
patients in Zhejiang have been treated with HAART.
The number of newly diagnosed HIV cases has stead-
ily increased between 2008 and 2012 (from 1066 to 2744 
patients). Despite HAART treatment, the number of 
HIV/AIDs patients in Zhejiang has increased. There-
fore, it is essential that we understand the efficacy of cur-
rent HIV/AIDS management strategies so that we can 
develop supplementary measures that will delay or pre-
vent the progression of AIDS and, ultimately, reduce the 
rate of mortality.
Previous studies involving mathematical prediction 
models suggest that HIV-infected patients to in develop-
ing countries are more likely to acquire AIDS and subse-
quently die compared with those in developed countries 
[8–10]. In this study, we retrospectively analyzed data 
from HIV-infected patients in Zhejiang collected from 
2008 to 2012. The goal of this study was to utilize patient 
data to identify risk factors associated with AIDS pro-
gression. Because China is the largest developing country 
in the world, this study examined whether the risk factors 
identified in developed countries might also be responsi-
ble for AIDS progression in developing countries.
Methods
Data source
A retrospective cohort study was conducted to evaluate 
the progression of HIV to AIDS in HIV-infected patients 
from Zhejiang, China. We utilized patient data from the 
Chinese National Case Reporting System collected from 
January 1, 2008 to December 31, 2012. After patients 
had been positively confirmed as HIV-positive, a uni-
form questionnaire designed by the Chinese Centers for 
Disease Control was used to collect patient information. 
The data were then uploaded to the National Surveillance 
System Database and the National Treatment Database. 
Patient information is confidential and could not be 
released without permission. Information retrieved from 
these databases included the following: demographic 
characteristics, disease progression (HIV or AIDS), year 
of confirmed diagnosis, method of diagnosis, transmis-
sion mode, dates, as well as details regarding AIDS pro-
gression and treatment [e.g., date of AIDS onset, HAART 
treatment dates, death (if applicable) CD4+ T-cell 
count]. After diagnosis, patients were followed until they 
died, were lost from the database, or until December 31, 
2012. Observation stops once AIDS were developed.
Sampling method
Between January 1, 2008 and December 31, 2012, a total 
of 9216 HIV-positive patients were enrolled in Group 
One. All participants had to meet the following crite-
ria: diagnosed as HIV-positive before 2008 and alive on 
December 31, 2007 or newly diagnosed with HIV during 
2008 to 2012; HIV-positive status was defined as testing 
positive for an HIV-1 on ELISA and Western blot analy-
sis. During the 5 years study observation, 441 (4.8 %) sub-
jects died or dropped out of the database.
Our analysis also focused on the role of potential risk 
factors in HIV progression to AIDS. Therefore, Group 
Two consisted of patients with the following characteris-
tics: newly diagnosed as HIV-positive from 2008 to 2012, 
had CD4+ T-cell count tested within 3  months after 
diagnosis, no immediate progression to AIDS. Of the 
9216 patients, 4121 had AIDS at the time of HIV-positive 
diagnosis to AIDS. Patients who developed AIDS within 
6 months after HIV diagnosis, or patients without a CD4 
test within 3 month after diagnosis were excluded in the 
study to reduce bias. Thus, 3898 patients were enrolled in 
group two.
Diagnosis of AIDS
In 2006, the World Health Organization (WHO) stated 
the progression of HIV to AIDS has occurred when an 
individual has a CD4+ T-cell count less than or equal to 
200 cells/mm3, or WHO stage 3 or 4 [11].
Statistical analysis
The survival time of those patients diagnosed with 
AIDS was estimated by the number of years from their 
first visit to the midpoint between the last visit with 
AIDS-free and the first visit with AIDS. Individuals who 
remained AIDS-free were monitored until their last fol-
low-up visit. All statistical analyses for this report were 
conducted using SPSS 17.0 statistical analysis software 
package (SPSS, Chicago, IL, USA). Data from Group One 
were analyzed using an abridged life table method, which 
Page 3 of 8Chen et al. AIDS Res Ther  (2015) 12:32 
described the incidence of AIDS from 2008 to 2012; and 
estimate the effect of HAART treatment on patient out-
comes. For Group Two, Cox proportional hazards mod-
els were fitted to examine the effects of region, gender, 
age, education, marriage, occupation, CD4+ T-cell count 
and HAART treatment on the time to between HIV diag-
nosis and AIDS diagnosis. Results with p values of less 
than 0.05 were considered statistically significant. We 
excluded patients with missing data from the analysis.
Results
Patient characteristics
The mean age of the 9216 HIV-positive patients enrolled 
in Group One was 35  years (range  =  1–88  years). In 
this study, the majority of patients were men (75.6  %) 
and 45.3  % were married. In terms of educational level, 
approximately 69.0  % patients did not proceed beyond 
junior high school. Additionally, 47.4  % patients were 
migrants from other provinces and most patients held 
one of the following jobs:worker, famer and commercial 
servant (64.3  %). Patients demographic characteristics 
are presented in Table 1.
AIDS development from 2008 to 2012
A total of 9216 patients in Group One were followed 
up for 12,452 person-years (py). By December 31, 2012, 
3868 patients progressed from HIV to AIDS in Group 
one. There were 441 patients who returned to their home 
country or died (ranging from 0.30 to 4.70 person-years 
following HIV diagnosis). Following HIV diagnosis, the 
mean CD4+ T-cell count was 437 cells/mm3. No signifi-
cant differences between the demographic characteristics 
of patients who stopped being monitored during the time 
of our study compared with those patients whose infor-
mation was available throughout the study time frame 
(data not shown) (Table 2).
During the entire observation period (2008–2012), 
HIV-positive patients progressed to AIDS (Group one) 
at the following rates: 33.9  % (2008), 33.6  % (2009), 
38.1 % (2010), 30.6 % (2011) and 25.9 % (2012) (Table 2). 
The cumulative AIDS incidence probability were 33.43, 
35.37, 36.38, 36.96 and 37.04 % in 1–5 years of follow-up, 
respectively (Table 3).
AIDS progression in patients treated with HAART
The prevalence of AIDS in Zhejiang from 2008 to 2010 
was 35.7 %, and it decreased to 27.9 % between 2011 and 
2012 (Table  2). To initially qualify for treatment with 
HAART (2008–2010), patients needed a CD4+ T-cell 
count of less than or equal to 200 cells/mm3; however, 
the eligibility for HAART treatment was broadened to 
include patients with a CD4+ T-cell count of less than 
350 cells/mm3 (2011–2012) (Table  2). Figure  1 show 
that AIDS progression rates decreased in all CD4 level 
groups except the unknown one. The largest reduc-
tion in the rate of AIDS progression was observed in 
patients with a baseline CD4+ T-cell count of 200–350 
cells/mm3 (25.8/100 py of the patients in 2008–2010 and 
17.7/100  py of the patients in 2011–2012, P  <  0.001). 
Figure 2 indicates that the progression rates for all modes 
of transmission decreased after the eligibility criteria 
for HAART were broadened to include patients with a 
CD4+ T-cell count of less than 350 cells/mm3. In par-
ticular, patients who were infected by HIV through 
homosexual transmission showed the most dramatic 
Table 1 Selected characteristics of patients with HIV infec-
tion in Zhejiang province
Characteristic Number (total = 9216) %
Sex
 Male 6961 75.6
 Female 2242 24.4
Occupation
 Farmer 1788 19.4
 Worker 2365 25.7
 Unemployed 994 10.8
 Commercial service 1764 19.2
 Doctor, teacher, retired people, govern-
ment officials
526 5.7
 Others 1766 19.2
Marriage
 Unmarried 3396 36.9
 Married 4166 45.3
 Divorced or widowed 1588 17.3
 Unknown 53 0.6
Ethnic group
 Han 8548 92.9
 Other 651 7.1
 Unknown 4 0.0
Education
 Primary school or under 2461 26.7
 Junior high school 3879 42.1
 Senior high school 1634 17.8
 College or above 1226 13.3
 Unknown 3 0.0
Age (years)
 0–24 1964 21.3
 25–34 3196 34.7
 35–44 2215 24.1
 45–54 993 10.8
 55 or above 835 9.1
Census register
 Zhejiang Province 4837 52.6
 Other Province 4366 47.4
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reduction in the rates of AIDS (36.2/100 py in 2008–2010 
to 23.6/100 py in 2011–2012, P < 0.001).
Changes over calendar time
The demographic characteristics of patients changed 
over the course of this study, from 2008 to 2012. In 2012, 
patients with first positive HIV test had a higher median 
age (39.8  years) compared with that of the comparable 
group of patients in 2008 (37.9 years old) (P < 0.05); HIV 
infection from homosexual transmission occurred more 
frequently in patients in 2012 (36.4 %) compared with in 
2008 (18.8 %) (P < 0.001); However, baseline CD4 T-cell 
count counts were similar in 2008 and 2012 (median: 
319 and 328 cell/μl, respectively; P  >  0.05); The rate of 
HAART treatment during the first year of diagnosed with 
HIV was significantly higher (27.5  %) in 2012 than in 
2008 (3.1 %) (P < 0.001).
Risk factors involved in the progression of HIV to AIDS
Patients in Group Two (3989 patients) were fol-
lowed up for 12,452  py. As of December 31, 2012, it 
was known that 611 patients had progressed to AIDS. 
Cox proportional hazards regression was performed 
to determine the relative contribution of each factor 
(i.e., demographic characteristics, mobility, transmis-
sion routes, year of diagnosis, treatment with HAART 
and CD4+ T-cell count at baseline) to the progres-
sion of HIV of AIDS (Table 4). Cox regression analysis 
revealed that several factors, including age at diagnosis, 
transmission routes, census register, year of diagnosis, 
baseline CD4+ T-cell count and CD4+ T-cell count 
Table 2 AIDS progression rates by time period
* Pearson χ2  test, P value for AIDS progression rates 2008–2010 vs. 2011–2012 of whole group, male and female are 0.000, 0.000, 0.002, respectively








AIDS, n (py) AIDS progression 
rate (/100 py)
AIDS, n (py) AIDS progression 
rate (/100 py)
2008 1093 370 33.9 243 (714) 34.0 127 (379) 33.6
2009 1626 546 33.6 395 (1112) 35.5 151 (514) 29.4
2010 2296 874 38.1 676 (1618) 41.8 198 (678) 29.2
2008–2010 5015 1790 35.7* 1314 (3444) 38.2* 476 (1571) 30.3*
2011 3163 969 30.6 726 (2317) 31.3 243 (846) 28.7
2012 4274 1109 25.9 869 (3232) 26.9 240 (1042) 23.0
2011–2012 7437 2078 27.9* 1595 (5549)* 28.8* 483 (1888) 25.6*








0– 2763 33.43 33.43
1– 335 5.81 35.37
2– 151 2.84 36.38
3– 81 1.59 36.96
4– 12 0.24 37.04
Total 3342 – –
Fig. 1 AIDS progression rates by baseline CD4+ cell count among 
2008–2012: this figure demonstrated the progression of HIV to AIDS 






































Fig. 2 AIDS progression rates by mode of transmission among 
2008–2012: this figure demonstrated the progression of HIV to AIDS 
among patients with different transmission routes
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Table 4 Cox proportional hazards model of risk factors for development of AIDS
Risk factor Unadjusted relative hazard P Adjusted relative hazard P
HR (95 % CI) HR (95 % CI)
Sex
 Male 1 (reference) – –
 Female 0.996 (0.827–1.200) 0.966 – –
Age (year)
 0~ 1 (reference) 1 (reference)
 25~ 1.176 (0.949–1.457) 0.139 1.221 (0.982–1.518) 0.072
 35~ 1.310 (1.031–1.666) 0.027 1.364 (1.065–1.746) 0.014
 45~ 1.556 (1.167–2.075) 0.003 1.692 (1.247–2.297) 0.001
 55~ 1.950 (1.412–2.694) 0.000 1.915 (1.357–2.703) 0.000
Education
 Primary school and under 1 (reference) – –
 Junior high school 0.981 (0.798–1.206) 0.856 – –
 Senior high school 0.943 (0.739–1.205) 0.641 – –
 College and above 0.874 (0.673–1.135) 0.312 – –
Marital status
 Single 1 (reference) – –
 Married 1.198 (1.007–1.425) 0.042 – –
 Divorced or widowed 1.094 (0.863–1.386) 0.457 – –
 Unknown 1.313 (0.486–3.526) 0.590 – –
Mode of transmission
 Homosexual contact 1 (reference) 1 (reference)
 Heterosexual contact 1.019 (0.862–1.205) 0.824 0.695 (0.571–0.844) 0.000
 Blood 0.789 (0.514–1.212) 0.279 0.524 (0.336–0.816) 0.004
 Other and unknown 0.951 (0.470–1.927) 0.890 0.689 (0.336–1.415) 0.311
Testing mode
 VCT consultant 1 (reference) –
 Health checkup 1.027 (0.807–1.306) 0.831 – –
 Seeing doctor for other disease 1.261 (1.006–1.579) 0.044 – –
 Spouse and children of patient, blood donors 1.380 (1.007–1.891) 0.045 – –
 Others 1.112 (0.720–1.718) 0.633 – –
Census register
 Zhejiang Province 1 (reference) 1 (reference)
 Other Province 0.765 (0.651–0.898) 0.001 0.670 (0.562–0.799) 0.000
Mobility
 Between Provinces 1 (reference) – –
 Between Cites 0.905 (0.636–1.287) 0.579 – –
 Between County 0.977 (0.777–1.228) 0.840 – –
 Immobility 0.970 (0.795–1.182) 0.761 – –
Reported time (year)
 2008–2010 1 (reference) 1 (reference)
 2011–2012 0.346 (0.274–0.437) 0.000 0.382 (0.302–0.483) 0.000
Baseline CD4+ T-cell count
 200–350 1 (reference) 0.000 1 (reference)
 350–500 0.464 (0.388–0.556) 0.000 0.380 (0.316–0.458) 0.000
 >500 0.262 (0.206–0.332) 0.000 0.187 (0.147–0.239) 0.000
CD4+ T-cell count of initial HAART
 No HAART 1 (reference) 1 (reference)
 ≤200 2.166 (1.273–3.685) 0.004 1.165 (0.679–1.999) 0.580
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of initial HAART played significant influence roles in 
the progression of HIV to AIDS. HIV patients older 
than 55  years showed a higher risk of progressing to 
AIDS than patients who were younger than 25  years 
old (HR  =  1.915, 95  % CI: 1.357–2.703, P  <  0.001). 
The rate of AIDS progression was significantly higher 
among those infected by homosexual transmission than 
among patients infected by heterosexuals transmis-
sion (HR = 0.695, 95 % CI: 0.571–0.844, P < 0.05) or by 
blood borne transmission (HR = 0.524, 95 % CI: 0.336–
0.816, P < 0.05). Patients diagnosed with HIV between 
2011 and 2012 were at a lower risk of acquiring AIDS 
than were those patients diagnosed between 2008 and 
2010 (HR  =  0.382, 95  % CI: 0.302–0.483, P  <  0.001). 
Our results also indicate that a higher CD4+ T-cell 
count was associated with a lower rate of AIDS pro-
gression (HR =  0.380, 0.187, P  <  0.001). Patients with 
a CD4+ T-cell count of 200–350 cells/mm3 or greater 
than 350 cells/mm3 were less likely to develop AIDS 
following HIV diagnosis than were those patients with-
out HAART treatment (HR =  0.225, 0.168, P  <  0.001) 
(Table 4).
Discussion
The rate at which HIV progressed to AIDS decreased 
from 33.9 % in 2008 to 25.9 % in 2012. These rates were 
greater than those observed in developed countries, such 
as British Columbia (7 % in 2013), Brazil (6.2 % between 
2000 and 2008), but they were similar to the rates in 
Africa and Asia countries [12–16]. In this study, AIDS 
was diagnosed within 1 year of HIV diagnosis, which is 
similar to the diagnostic process in developed countries. 
The rates at which patients diagnosed with HIV pro-
gressed to AIDS within 12  months in developed coun-
tries were as follows: Australia: 65.0  %, Canada: 64.0  % 
and France: 64.8 % [17]. Our study found late diagnosis 
of HIV in Zhejiang and other Chinese provinces, which 
probably affects the survival of patients.
Several studies in developed countries have demon-
strated that non-HAART treatment, hepatitis B coinfec-
tion, tuberculosis coinfection, being older than 50 years 
of age, having black or brown skin, intravenous drug 
abuse, lack of schooling as well as a baseline CD4+ T-cell 
count lower than 500 cells/mm3 were predictors of higher 
rate of AIDS progression [18–20].
The results from our study suggest that increasing the 
CD4+ T-cell count necessary to begin HAART treat-
ment is an effective way to delay AIDS progression 
among PLHIV. The overall AIDS progression rate under-
went a steady reduction after 2010 (from 38.1 to 25.9 %) 
as the treatment was available to patients with a CD4+ 
T-cell count of 350  cells/mm3 [21]. Our analysis also 
indicated that patients with a CD4+ T-cell count greater 
than 200–350 cells/mm3 benefit the most from early 
HAART treatment. The progression rate for patients 
with unknown CD4+ T-cell counts increased over time, 
with 33.5 % of these patients being diagnosed at the time 
of death. We hypothesize that these phenomena relate to 
the fact that these specific individuals did not seek care in 
time. Furthermore, most of these patients were migrants, 
had lower lever of education, and older. HAART plays 
an important role in delaying the progression of HIV to 
AIDS because it can reduce the HIV–RNA concentra-
tion and restoring the immune system [22–24]. In recent 
years, increasing number of researches encouraged early 
treatment with CD4+ T-cell count less than 500 cells/
mm3 or more [25–27]. Although the beneficial effects 
of HAART have been already observed in patients with 
a CD4+ T-cell count greater than 200  cells/mm3, or 
greater than or equal to 350 cells/mm3, developing coun-
ties, including Asia and Africa, need to understand other 
important factors [e.g. economic factors, side effects or 
serious non AIDS events (ANAEs) like cancer and car-
diovascular disease].
Several factors, including mode of transmission, region, 
age and CD4+ T-cell count at baseline were related to 
the rate of AIDS progression in HIV-positive patients. 
A study performed by Hongjing Yan found a higher rate 
of disease progression from HIV to AIDS among homo-
sexuals compared with among heterosexuals, intravenous 
drug users (IDUs) or blood donors [8]. Similar results 
were observed in this study; however, the proportion of 
late diagnosis in male who have sex with male (MSM) 
patients was 19.1  %, which was lower than that of het-
erosexuals (30.9 %) and others (29.7 %) in Zhejiang (data 
not published). The high rate of AIDS progression among 
homosexual patients might be a result of other important 
factors including stigma, psychological characteristics, 
genetic or molecular characteristics, as well as coinfec-
tion with other disease, such as hepatitis; or tuberculosis 
Table 4 continued
Risk factor Unadjusted relative hazard P Adjusted relative hazard P
HR (95 % CI) HR (95 % CI)
 200–350 0.402 (0.320–0.504) 0.000 0.225 (0.178–0.285) 0.000
 >350 0.295 (0.110–0.789) 0.015 0.168 (0.063–0.451) 0.000
VCT voluntary counselling test
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[28]. Although this information was not collected in our 
particular patient database, further investigations are 
warranted. In Zhejiang, the central regions have the high-
est rate of AIDS development, which might be related to 
the fact that these regions contain the highest propor-
tions of homosexuals. A study in Hangzhou conducted 
between 2006 and 2008 indicated that the infection rates 
of homosexuals from pubs, bathrooms and clubhouses 
were 3.5, 12.8 and 2.8  %, respectively, all of which were 
higher than those observed in any other cities in Zhe-
jiang [29, 30]. The results of our study also suggest that 
age and baseline CD4+ T-cell count were critical factors 
that determine the rate of progression of HIV to AIDS. 
Patients who have lower baseline CD4+ T-cell count and 
were of an older age tended to have a higher %consistent 
with previously published works [31].
This retrospective cohort study of patients from Zhe-
jiang, provides information on the rate and contributors 
to the progression of HIV to AIDS. Our observations 
highlight the impact of late HIV testing and delayed diag-
nosis of HIV/AIDS in Zhejiang. Previous studies have 
suggested that an undamaged immune system predicts 
delayed progression to AIDS [32] and late diagnosis leads 
to exhaustion of the immune system. Therefore, the use 
of additional strategies, such as VCT and provider-initi-
ated HIV testing and counseling (PITC), for HIV screen-
ing is necessary to delay the progression of HIV to AIDS.
Limitations
This has a few limitations. As the cohort was not strictly 
designed, inaccurate follow-up was inevitable. First, the 
amount of time between HIV diagnosis to AIDS diag-
nosis might have been exaggerated or underestimated. 
Second, CD4+ T-cell count, which is an important diag-
nostic tool for AIDS, was not available for all patients. 
A large number subjects are excluded in group two for 
their AIDS status as diagnosis and without CD4+ T-cell 
count in first 3 month following diagnosis were excluded 
for confounding variables, which may have introduced 
selection bias. Although we recommend early HAART 
treatment, data on side effect or additional information 
regarding earlier treatment have not been reported. The 
role of early HAART treatment in patient health will 
need to be assessed in the future.
Conclusions
In conclusion, HIV progression to AIDS was affected by 
the patient’s age at diagnosis, transmission routes and 
baseline CD4+ T-cell counts. Early HAART treatment 
in patients with a higher CD4+ T-cell count significantly 
delayed progression to AIDS in these patients. Thus 
effective interventions, such as PITC or VCT, should be 
utilized to target those at high risk. Our results support 
use of early HAART treatment, an approach that is 
already recommended by the current WHO treatment 
guidelines for HIV infection.
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